Arterial hypertension and bronchial asthma: key risk factors

The article was submitted 30.10.2025; approved after reviewing 18.01.2026; accepted for publication 02.02.2026
Modern medicine is faced with an increasing number of patients suffering from multiple chronic diseases simultaneously. The presence of two or more conditions increases the complexity of diagnosis, appropriate treatment selection, and patient care. People with a combination of several chronic non-communicable diseases are more likely to face disability, restrictions in daily activities, and a reduced quality of life. The prevalence of cardiovascular diseases and diseases of the bronchopulmonary system remains high. In addition, they often have common risk factors and pathogenetic interactions. This article examines the problem of the combination of bronchial asthma and hypertension from the perspective of common risk factors and pathophysiological relationships.

1. Bush A. Pathophysiological Mechanisms of Asthma // Front. Pediatr. 2019. Vol. 7. P. 68. https://doi.org/10.3389/fped.2019.00068.

2. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 // Lancet. 2020. Vol. 396, № 10258. P. 1204–22. https://doi.org/10.1002/dmrr.3572/v2/review1.

3. Chuchalin A. G., Khaltaev N., Antonov N. S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation // Int. J. Chron. Obstruct. Pulmon. Dis. 2014. Vol. 9, № 1. P. 963–974. https://doi.org/10.2147/COPD.S67283.

4. Rogliani P., Sforza M., Calzetta L. The impact of comorbidities on severe asthma // Curr. Opin. Pulm. Med. 2020. Vol. 26. P. 47–55. https://doi.org/10.1097/MCP.0000000000000640.

5. Tay T. R., Hew M. Comorbid “treatable traits” in difficult asthma: Current evidence and clinical evaluation // Allergy. 2017. Vol. 73. P. 1369–1382. https://doi.org/10.1111/all.13370.

6. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension // European heart journal. 2018. Vol. 33, № 39. P. 3021–3104. https://doi.org/10.1097/hjh.0000000000002017.

7. Yaacoub S., Boudaka A., AlKhatib A. et al. The pharmaco-epigenetics of hypertension: a focus on microRNA. Mol Cell Biochem. 2024. Vol. 479, № 12. P. 3255–3271. https://doi.org/10.1007/s11010-024-04947-9.

8. Cazzola M., Calzetta L., Bettoncelli G. et al. Cardiovascular disease in asthma and COPD: A population-based retrospective cross- sectional study // Respir Med. 2012. Vol. 106. P. 249–56. https://doi.org/10.1016/j.rmed.2011.07.021.

9. Zhao R., Xu R., Yuan J. et al. Asthma risk: the inseparable synergy of obesity and metabolism // BMC Pulm Med. 2025. Vol. 25. Art. 409. https://doi.org/10.1186/s12890-025-03878-5.

10. Chen Y., Dales R., Krewski D., Breithaupt K. Increased effects of smoking and obesity on asthma among female Canadians: the National Population Health Survey, 1994-1995 // Am J Epidemiol. 1999. Vol. 150, № 3. P. 255–62. https://doi.org/10.1093/oxfordjournals.aje.a009996.

11. Çolak Y., Afzal S., Nordestgaard B. G., Lange P. Characteristics and prognosis of never-smokers and smokers with asthma in the Copenhagen General Population Study. A prospective cohort study // Am J Respir Crit Care Med. 2015. Vol. 192. P. 172–81. https://doi.org/10.1164/rccm.201502-0302oc.

12. Braido F., Brusselle G., Guastalla D. et al. Determinants and impact of suboptimal asthma control in Europe: the International Cross-sectional and Longitudinal Assessment on Asthma Control (LIAISON) study // Respir Res. 2016. Vol. 17. P. 51. https://doi.org/10.1186/s12931-016-0374-z.

13. James A. L., Palmer L. J., Kicic E. et al. Decline in lung function in the Busselton health study: the effects of asthma and cigarette smoking // Am J Respir Crit Care Med. 2005. Vol. 171. P. 109–114. https://doi.org/10.1164/rccm.200402-230oc.

14. Takahashi K., Pavlidis S., Ng Kee Kwong F. et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis // Eur Respir J. 2018. Vol. 51. P. 1702173. https://doi.org/10.1183/13993003.02173-2017.

15. Strzelak A., Ratajczak A., Adamiec A., Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review // Int J Environ Res Public Health. 2018. Vol. 15. P. 1033. https://doi.org/10.3390/ijerph15051033.

16. Klein D. K., Silberbrandt A., Frøssing L. et al. Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma // Eur Respir J. 2022. Vol. 60. P. 2102446. https:// doi.org/10.1183/13993003.02446-2021.

17. Wu D., Lai T., Yuan Y. et al. Elevated expression of placental growth factor is associated with airway-wall vascular remodelling and thickening in smokers with asthma // Sci Rep. 2017. Vol. 7. P. 43017. https://doi.org/10.1038/srep43017.

18. Boulet L.-P., Lemiere C., Archambault F. et al. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation // Chest. 2006. Vol. 129. P. 661–8. https://doi.org/10.1016/s8756-3452(08)70298-6.

19. Stanescu D., Sanna A., Veriter C. et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils // Thorax. 1996. Vol. 51. P. 267–271. https://doi.org/10.1136/thx.51.3.267.

20. Madani A., Alack K., Richter M. J., Krüger K. Immune-regulating effects of exercise on cigarette smoke-induced inflammation // J Inflamm Res. 2018. Vol. 11. P. 155–167. https://doi.org/10.2147/jir.s141149.

21. Middlekauff H. R., Park J., Agrawal H., Gornbein J. A. Abnormal sym- pathetic nerve activity in women exposed to cigarette smoke: a potential mechanism to explain increased cardiac risk // Am J Physiol Heart Circ Physiol. 2013. Vol. 305. P. H1560–H1567. https://doi.org/10.1152/ ajpheart.00502.2013.

22. Rahman S. M., Ji X., Zimmerman L. J. et al. The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer // JCI Insight. 2016. Vol. 1. P. e88814. https://doi.org/10.1172/jci.insight.88814.

23. Freed J. K., Beyer A. M., LoGiudice J. A. et al. Ceramide changes the mediator of flow-induced vasodilation from nitric oxide to hydrogen peroxide in the human microcirculation // Circ Res. 2014. Vol. 115. P. 525–532. https://doi.org/10.1161/CIRCRESAHA.115.303881.

24. Dikalova A. E., Itani H. A., Nazarewicz R. R. et al. Sirt3 impairment and SOD2 hyperacetylation in vascular oxidative stress and hypertension // Circ Res. 2017. Vol. 121. P. 564–574. https://doi.org/10.1161/CIRCRESAHA.117.310933.

25. Dimitriadis K., Narkiewicz K., Leontsinis I. et al. Acute Effects of Electronic and Tobacco Cigarette Smoking on Sympathetic Nerve Activity and Blood Pressure in Humans // Int J Environ Res Public Health. 2022. Vol. 19, № 6. P. 3237. https://doi.org/10.3390/ijerph19063237.

26. Osei A. D., Mirbolouk M., Orimoloye O. A. et al. The association between e-cigarette use and asthma among never combustible cigarette smokers: Behavioral risk factor surveillance system (BRFSS) 2016 & 2017 // BMC Pulm. Med. 2019. Vol. 19. P. 180. https://doi.org/10.1186/ s12890-019-0950-3.

27. Traboulsi H., Cherian M., Abou Rjeili M. et al. Inhalation Toxicology of Vaping Products and Implications for Pulmonary Health // Int. J. Mol. Sci. 2020. Vol. 21. P. 3495. https://doi.org/10.3390/ijms21103495.

28. Hickman E., Jaspers I. Current E-Cigarette Research in the Context of Asthma. Curr. Allergy Asthma Rep. 2020. Vol. 20, № 10. P. 62. https:// doi.org/10.1007/s11882-020-00952-2.

29. St Claire S., Gouda H., Schotte K. et al. Lung health, tobacco, and related products: Gaps, challenges, new threats, and suggested research // Am. J. Physiol. Lung Cell Mol. Physiol. 2020. Vol. 318. P. L1004–L1007. https://doi.org/10.1152/ajplung.00101.2020.

30. Casey A. M., Muise E. D., Crotty Alexander L. E. Vaping and e-cigarette use. Mysterious lung manifestations and an epidemic // Curr. Opin. Immunol. 2020. Vol. 66. P. 143–150. https://doi.org/10.1016/j.coi.2020.10.003.

31. Galderisi A., Ferraro V. A., Caserotti M. et al. Protecting youth from the vaping epidemic // Pediatr. Allergy Immunol. 2020. Vol. 31. P. 66–68. https://doi.org/10.1111/pai.13348/v2/response1.

32. Hernandez M. L., Burbank A. J., Alexis N. E. et al. Electronic Cigarettes and Their Impact on Allergic Respiratory Diseases: AWork Group Report of the AAAAI Environmental Exposures and Respiratory Health Committee // J. Allergy Clin. Immunol. Pract. 2021. Vol. 9. P.1142–1151. https://doi.org/10.1016/j.jaip.2020.12.065.

33. Beuther D. A., Sutherland E. R. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies // Am J Respir Crit Care Med. 2007. Vol. 175. P. 661–6. https://doi.org/10.1164/rccm.200611-1717oc.

34. Uysal K. T., Wiesbrock S. M., Marino M. W., Hotamisligil G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function // Nature. 1997. Vol. 389. P. 610–614. https://doi.org/10.1038/39335.

35. Ventre J., Doebber T., Wu M. et al. Targeted disruption of the tumor necrosis fac- tor-alpha gene: metabolic consequences in obese and nonobese mice // Diabetes. 1997. Vol. 46. P. 1526–1531. https://doi.org/10.2337/diabetes.46.9.1526.

36. Nara N., Nakayama Y., Okamoto S. et al. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance // J. Biol. Chem. 2007. Vol. 282. P. 30794–30803. https://doi.org/10.1074/jbc.M700412200.

37. Huber J., Kiefer F. W., Zeyda M. et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity // J. Clin. Endocrinol. Metab. 2008. Vol. 93. P. 3215–3221. https://doi.org/10.1210/jc.2007-2630.

38. Duffaut C., Zakaroff-Girard A., Bourlier V. et al. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators // Arterioscler. Thromb. Vasc. Biol. 2009. Vol. 29. P. 1608–1614. https:// doi.org/10.1161/ATVBAHA.109.192583.

39. Stefanovic-Racic M., Yang X., Turner M. S. et al. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver // Diabetes. 2012. Vol. 61. P. 2330–2339. https://doi.org/10.2337/db11-1523.

40. Bertola A., Ciucci T., Rousseau D. et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients // Diabetes. 2012. Vol. 61. P. 2238–2247. https://doi.org/10.2337/db11-1274.

41. Liu J., Divoux A., Sun J. et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice // Nat. Med. 2009. Vol. 15. P. 940–945. https://doi.org/10.1038/nm.1994.

42. Nishimura S., Manabe I., Nagasaki M. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity // Nat. Med. 2009. Vol. 15. P. 914–920. https://doi.org/10.1038/nm.1964.

43. Sideleva O., Suratt B. T., Black K. E. et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway // Am J Respir Crit Care Med. 2012. Vol. 186, Iss. 7. P. 598–605. https://doi.org/10.1164/rccm.201203-0573oc.

44. Eising J. B., Uiterwaal C. S., Evelein A. M. et al. Relationship between leptin and lung function in young healthy children // Eur Respir J. 2014. Vol. 43. P. 1189–92. https://doi.org/10.1183/09031936.00149613.

45. Kattan M., Kumar R., Bloomberg G. R. et al. Asthma control, adiposity, and adipokines among inner-city adolescents // J Allergy Clin Immunol. 2010. Vol. 125, № 3. P. 584–92. https://doi.org/10.1016/j.jaci.2010.01.053.

46. Sood A., Shore S. A. Adiponectin, Leptin, and Resistin in Asthma: Basic Mechanisms through Population Studies // J Allergy (Cairo). 2013. Vol. 2013. P. 785835. https://doi.org/10.1155/2013/785835.

47. Huang F., Del-Rio-Navarro B. E., Torres-Alcantara S. et al. Adipokines, asymmetrical dimethylarginine, and pulmonary function in adolescents with asthma and obesity // J Asthma. 2017. Vol. 54. P. 153–61. https://doi.org/10.1080/02770903.2016.1200611.

48. Wang Y., Wang Q. J. The prevalence of prehypertension and hyper- tension among US adults according to the new Joint National Committee guidelines // Arch Intern Med. 2004. Vol. 164. P. 2126–2134. https://doi.org/10.1001/archinte.164.19.2126.

49. Lohmeier T. E., Iliescu R. The sympathetic nervous system in obesity hypertension // Curr Hypertens Rep. 2013. Vol. 15, № 4. P. 409–16. https://doi.org/10.1007/s11906-013-0356-1.

50. Virdis A. Endothelial dysfunction in obesity: role of inflammation // High Blood Press Cardiovasc Prev. 2016. Vol. 23. P. 83–85. https://doi.org/10.1007/s40292-016-0133-8

51. Peng Y., Croce C. M. The role of MicroRNAs in human cancer // Signal. Transduct. Target. Ther. 2016. Vol. 1. P. 15004. https://doi.org/10.1038/sigtrans.2015.4.

52. Zhang Z., Zhuang L., Lin C.-P. Roles of MicroRNAs in Establishing and Modulating Stem Cell Potential // Int. J. Mol. Sci. 2019. Vol. 20. P. 3643. https://doi.org/10.3390/ijms20153643.

53. Vidigal J. A., Ventura A. The biological functions of miRNAs: Lessons from in vivo studies // Trends Cell Biol. 2015. Vol. 25. P. 137–147. https://doi.org/10.1016/j.tcb.2014.11.004.

54. Vorobeva E. V., Kyyaly M. A., Sones C. L. et al. Circulating microRNAs as Potential Diagnostic Tools for Asthma and for Indicating Severe Asthma Risk // Int. J. Mol. Sci. 2025. Vol. 26. P. 6676. https://doi.org/10.3390/ijms26146676.

55. Zolotareva O., Saik O. V., Königs C. et al. Comorbidity of asthma and hypertension may be mediated by shared genetic dysregulation and drug side effects // Sci Rep. 2019. Vol. 9, № 1. P. 16302. https://doi.org/10.1038/s41598-019-52762-w. PMID: 31705029; PMCID: PMC6841742.

56. Li X., Wei Y., Wang Z. MicroRNA-21 and hypertension // Hypertens Res. 2018. Vol. 41. P. 649–661. https://doi.org/10.1038/s41440-018-0071-z.

57. Ashikha Shirin Usman P. P., Ameya K. P., Sekar D. Revolutionary advances in hypertension detection: Gold nanoparticle-enhanced miRNA-based electrochemical biosensors and emerging nanotechnologies // Human Gene. 2025. Vol. 44. P. 201401. https://doi.org/10.1016/j.humgen.2025.201401.

58. Ozkan G., Ulusoy S., Geyik E., Erdem Y. Down-regulation of miRNA 145 and up-regulation of miRNA 4516 may be associated with primary hypertension // J Clin Hypertens (Greenwich). 2019. Vol. 21. P. 1724–1731. https://doi.org/10.1111/jch.13704.

59. Adamcova M., Kawano I., Simko F. The impact of microRNAs in renin- angiotensin-system-induced cardiac remodeling // Int J Mol Sci. 2021. Vol. 22, № 9. P. 4762. https://doi.org/10.3390/ijms22094762.

60. Holtzman J., Lee H. Emerging role of extracellular vesicles in the respiratory system // Exp. Mol. Med. 2020. Vol. 52. P. 887–895. https://doi.org/10.1038/s12276-020-0450-9.

61. Atashbasteh M., Mortaz E., Mahdaviani S. A. et al. Expression levels of plasma exosomal miR-124, miR-125b, miR-133b, miR-130a and miR-125b-1-3p in severe asthma patients and normal individuals with emphasis on inflammatory factors // Allergy Asthma Clin. Immunol. 2021. Vol. 17. P. 1–12. https://doi.org/10.1186/s13223- 021-00556-z.

62. Ruan J., Yi X. Genomic structural equation modeling elucidates the shared genetic architecture of allergic disorders // J Transl Med. 2025. Vol. 23. P. 445. https://doi.org/10.1186/s12967-025-06465-8.

63. Kyyaly M. A., Vorobeva E. V., Kothalawala D. M. et al. MicroRNAs-a promising tool for asthma diagnosis and severity assessment: A systematic review // J. Pers. Med. 2022. Vol. 12. P. 543. https://doi.org/10.3390/jpm12040543.

64. Zhao M., Juanjuan L., Weijia F. et al. Expression Levels of MicroRNA- 125b in Serum Exosomes of Patients with Asthma of Different Severity and its Diagnostic Significance // Curr. Drug Metab. 2019. Vol. 20. P. 781–784. https://doi.org/10.2174/1389200220666191021100001.